TorreyPines says that a Phase IIb trial of its new migraine drug--tezampanel--achieved its primary endpoint of relieving pain at doses of 40 mg. The drug did not significantly reduce pain at doses of 70 mg and 100 mg. "These data demonstrate that tezampanel unequivocally relieved migraine pain at a dose that is safe and well-tolerated," said Neil Kurtz, M.D., President and CEO of TorreyPines. Release